-
公开(公告)号:US20090143385A1
公开(公告)日:2009-06-04
申请号:US12277331
申请日:2008-11-25
IPC分类号: A61K31/5377 , C07D413/02 , C07D413/14 , A61K31/501
CPC分类号: C07D413/12 , C07D413/14 , C07D487/04
摘要: The invention relates to isoxazolo-pyridazine compounds, in particular those of formula I as described above and to a pharmaceutically acceptable salts thereof, having affinity and selectivity for the GABA A α5 receptor binding site, their manufacture, pharmaceutical compositions containing them and their use as cognitive enhancers or for the treatment of cognitive disorders like Alzheimer's disease.
摘要翻译: 本发明涉及异恶唑并哒嗪化合物,特别是上述式I化合物及其可药用盐,对GABA Aα5受体结合位点具有亲和力和选择性,其制备方法,含有它们的药物组合物及其作为 认知增强剂或用于治疗认知障碍如阿尔茨海默病。
-
32.
公开(公告)号:US20070082936A1
公开(公告)日:2007-04-12
申请号:US11543178
申请日:2006-10-04
申请人: Bernd Buettelmann , Bo Han , Henner Knust , Matthias Nettekoven , Andrew Thomas
发明人: Bernd Buettelmann , Bo Han , Henner Knust , Matthias Nettekoven , Andrew Thomas
IPC分类号: A61K31/42 , C07D413/02
CPC分类号: C07D413/14
摘要: The present invention is concerned with aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives of formula I wherein R1, R2, R3, R4, and R5 are as defined in the specification and claims and with their pharmaceutically acceptable acid addition salts. The invention also relates to methods for preparing such compounds. This class of compounds has a high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease. Thus, the invention also is concerned with pharmaceutical compositions containing compounds of formula I or their pharmaceutically acceptable acid addition salts and methods for the treatment of GABA A α5 mediated diseases, including Alzheimer's disease.
摘要翻译: 本发明涉及式I的芳基 - 异恶唑-4-羰基 - 吲哚 - 羧酸酰胺衍生物,其中R 1,R 2,R 3, R 4,R 4和R 5如说明书和权利要求书及其药学上可接受的酸加成盐所定义。 本发明还涉及制备这些化合物的方法。 这类化合物对GABA Aα5受体结合位点具有高亲和力和选择性,可能作为认知增强剂或治疗阿尔茨海默病等认知障碍。 因此,本发明还涉及含有式I化合物或其药学上可接受的酸加成盐的药物组合物和用于治疗包括阿尔茨海默氏病在内的GABA Aα5介导的疾病的方法。
-
公开(公告)号:US20070066668A1
公开(公告)日:2007-03-22
申请号:US11520394
申请日:2006-09-13
申请人: Bernd Buettelmann , Bo Han , Henner Knust , Matthias Nettekoven , Andrew Thomas
发明人: Bernd Buettelmann , Bo Han , Henner Knust , Matthias Nettekoven , Andrew Thomas
IPC分类号: A61K31/42 , C07D413/02
CPC分类号: C07D413/14 , C07D413/06 , C07D451/06
摘要: The present invention is concerned with aryl-isoxazole-4-carbonyl-pyrrole-2-carboxylic acid amide derivatives of formula wherein R1, R2, R3, R4, and R5, and m are as defined herein and with their pharmaceutically acceptable acid addition salts. This class of compounds have high affinity and selectivity for GABA A α5 receptor binding sites and therefore may be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
摘要翻译: 本发明涉及下式的芳基 - 异恶唑-4-羰基 - 吡咯-2-羧酸酰胺衍生物其中R 1,R 2,R 3, R 4,R 4和R 5,m如本文所定义,并与其药学上可接受的酸加成盐反应。 这类化合物对GABA Aα5受体结合位点具有高亲和力和选择性,因此可用作认知增强剂或治疗认知障碍如阿尔茨海默病。
-
公开(公告)号:US20090197875A1
公开(公告)日:2009-08-06
申请号:US12422317
申请日:2009-04-13
申请人: Bernd Buettelmann , Bo Han , Henner Knust , Andreas Koblet , Andrew Thomas
发明人: Bernd Buettelmann , Bo Han , Henner Knust , Andreas Koblet , Andrew Thomas
IPC分类号: A61K31/541 , C07D413/14 , A61K31/5377 , C07D417/14
CPC分类号: C07D413/04 , C07D413/14
摘要: The present invention is concerned with isoxazol-4-yl-oxadiazole derivatives of formula wherein R1, R2, and R3, are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. This class of compounds has high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
摘要翻译: 本发明涉及下式的异恶唑-4-基 - 恶二唑衍生物,其中R 1,R 2和R 3如说明书中所定义及其药学上可接受的酸加成盐。 这类化合物对GABA Aα5受体结合位点具有高亲和力和选择性,可用作认知增强剂或用于治疗认知障碍如阿尔茨海默病。
-
公开(公告)号:US07414061B2
公开(公告)日:2008-08-19
申请号:US11640622
申请日:2006-12-18
申请人: Bernd Buettelmann , Bo Han , Henner Knust , Andrew Thomas
发明人: Bernd Buettelmann , Bo Han , Henner Knust , Andrew Thomas
IPC分类号: A61K31/506 , A61K31/4439 , A61K31/42 , C07D413/14
CPC分类号: C07D413/04
摘要: The present invention is concerned with aryl-isoxazol-4-yl-imidazole derivatives of formula I: wherein R1 to R6 are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. This class of compounds has high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
摘要翻译: 本发明涉及式I的芳基 - 异恶唑-4-基 - 咪唑衍生物:其中R 1至R 6如本说明书和药学上可接受的酸所定义 其加成盐。 这类化合物对GABA Aα5受体结合位点具有高亲和力和选择性,可用作认知增强剂或用于治疗认知障碍如阿尔茨海默病。
-
36.
公开(公告)号:US07378435B2
公开(公告)日:2008-05-27
申请号:US11543178
申请日:2006-10-04
申请人: Bernd Buettelmann , Bo Han , Henner Knust , Matthias Nettekoven , Andrew Thomas
发明人: Bernd Buettelmann , Bo Han , Henner Knust , Matthias Nettekoven , Andrew Thomas
IPC分类号: A61K31/42 , C07D413/02
CPC分类号: C07D413/14
摘要: The present invention is concerned with aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives of formula I wherein R1, R2, R3, R4, and R5 are as defined in the specification and claims and with their pharmaceutically acceptable acid addition salts. The invention also relates to methods for preparing such compounds. This class of compounds has a high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease. Thus, the invention also is concerned with pharmaceutical compositions containing compounds of formula I or their pharmaceutically acceptable acid addition salts and methods for the treatment of GABA Aα5 mediated diseases, including Alzheimer's disease.
摘要翻译: 本发明涉及式I的芳基 - 异恶唑-4-羰基 - 吲哚 - 羧酸酰胺衍生物,其中R 1,R 2,R 3, R 4,R 4和R 5如说明书和权利要求书及其药学上可接受的酸加成盐所定义。 本发明还涉及制备这些化合物的方法。 这类化合物对GABA Aα5受体结合位点具有高亲和力和选择性,可能作为认知增强剂或治疗阿尔茨海默病等认知障碍。 因此,本发明还涉及含有式I化合物或其药学上可接受的酸加成盐和用于治疗包括阿尔茨海默病在内的GABA Aalpha5介导的疾病的方法的药物组合物。
-
公开(公告)号:US20070287739A1
公开(公告)日:2007-12-13
申请号:US11805640
申请日:2007-05-24
申请人: Bernd Buettelmann , Henner Knust , Andrew Thomas
发明人: Bernd Buettelmann , Henner Knust , Andrew Thomas
IPC分类号: A61K31/42 , C07D261/06
CPC分类号: C07D413/06 , C07D261/08 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/14 , C07D471/04
摘要: The present invention is concerned with aryl-4-ethynyl-isoxazole derivatives of formula I wherein R1 to R5 are as described in the specification and pharmaceutically acceptable salt thereof. This class of compounds has high affinity and selectivity for GABA A α5 receptor binding sites, being useful as a cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
摘要翻译: 本发明涉及式I的芳基-4-乙炔基 - 异恶唑衍生物,其中R 1至R 5如说明书及其药学上可接受的盐所述。 这类化合物对GABA Aα5受体结合位点具有高亲和力和选择性,可用作认知增强剂或用于治疗认知障碍如阿尔茨海默病。
-
公开(公告)号:US20070161686A1
公开(公告)日:2007-07-12
申请号:US11639695
申请日:2006-12-15
申请人: Bernd Buettelmann , Bo Han , Henner Knust , Andreas Koblet , Andrew Thomas
发明人: Bernd Buettelmann , Bo Han , Henner Knust , Andreas Koblet , Andrew Thomas
IPC分类号: A61K31/4245 , C07D413/02
CPC分类号: C07D413/04 , C07D413/14
摘要: The present invention is concerned with isoxazol-4-yl-oxadiazole derivatives of formula wherein R1, R2, and R3, are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. This class of compounds has high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
摘要翻译: 本发明涉及下式的异恶唑-4-基 - 恶二唑衍生物其中R 1,R 2,R 3和R 3为 在本说明书中定义及其药学上可接受的酸加成盐。 这类化合物对GABA Aα5受体结合位点具有高亲和力和选择性,可用作认知增强剂或用于治疗认知障碍如阿尔茨海默病。
-
公开(公告)号:US08227461B2
公开(公告)日:2012-07-24
申请号:US12766202
申请日:2010-04-23
IPC分类号: A61K31/541 , A61K31/5377 , A61K31/4439 , C07D417/14 , C07D413/14 , C07D401/12
CPC分类号: C07D413/12 , C07D413/14
摘要: The present invention is concerned with novel isoxazole derivatives of formula I wherein X, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of the present invention have affinity and selectivity for GABA A α5 receptor. Further the present invention is concerned with the manufacture of the active compounds of formula I, pharmaceutical compositions containing them and their use as pharmaceuticals.
摘要翻译: 本发明涉及式I的新型异恶唑衍生物,其中X,R 1,R 2,R 3,R 4和R 5如本文所述,以及其药学上可接受的盐和酯。 本发明的活性化合物对GABA Aα5受体具有亲和性和选择性。 此外,本发明涉及制备式I的活性化合物,含有它们的药物组合物及其作为药物的用途。
-
公开(公告)号:US08173652B2
公开(公告)日:2012-05-08
申请号:US12704548
申请日:2010-02-12
IPC分类号: A61K31/5377 , A61K31/42 , A61K31/454 , C07D413/06 , C07D413/14
CPC分类号: C07D261/18 , C07D413/14 , C07D417/12 , C07D487/10
摘要: The present invention is concerned with isoxazole-isoxazoles and isoxazole-isothiazoles of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as cognitive enhancers or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease.
摘要翻译: 本发明涉及式I的异恶唑 - 异恶唑和异恶唑 - 异噻唑,对GABA Aα5受体具有亲和性和选择性,其制备方法,含有它们的药物组合物及其作为认知增强剂的用途或用于治疗和/或预防性治疗 认知障碍如阿尔茨海默病。
-
-
-
-
-
-
-
-
-